The National Institute of Food and Drug Safety Evaluation (NIFDS) said it would hold a conference on regulatory trends, vaccine development, and innovative drugs concerning Covid-19, along with the Drug Information Association from Sept. 2-3.
Officials from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) will participate in the online workshop.
Drug Information Association (DIA) is a U.S. organization established in 1964 and has members in 80 countries. It organizes conferences, runs regular training courses, and publishes journals concerning the development and approval of medicinal products to improve global healthcare.
During the two-day event, NIFDS will hold a joint online meeting to present the rapid development of Covid-19 treatments and vaccines, regulatory trends, and innovative drug development strategies with the two major global regulators.
FDA and EMA officials will speak about facilitating Covid-19 therapies and vaccines and related regulations on the first day. The next day, domestic pharmaceutical companies would explain their plans about novel drug developments and international patent protection, and FDA would introduce effective ways to speed up the developments.
The meeting was prepared to strengthen the international competitiveness of the domestic pharmaceutical and bio industry. The ministry invited regulators and domestic and foreign industry experts to share Covid-19 treatment vaccine development, regulatory trends, and strategies for developing innovative drugs in Korea to enter foreign markets.
Directors Peter Marks of Center for Biologics Evaluation and Research and John Farley Office of Infectious Diseases at FDA and EMA executive Thomas Larsson will present an overview of global regulatory trends for rapid response against Covid-19.
In addition, 17 lecturers, including experts from the pharmaceutical companies, will present the latest therapeutics and vaccines, experiences, and strategies for advancing to global markets.
“We believe the upcoming meeting will help strengthen the international competitiveness of the domestic biopharmaceutical industry and the cooperative system among regulatory agencies, such as sharing a safety management system for pharmaceuticals,” a ministry official said.